Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-1971 + Atezolizumab in Advanced Solid Tumors
NCT05487235Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of migoprotafib in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events (AEs) at 2.5 years, Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs at 2.5 years and 4 more. Started Aug 2022; status: completed.
02
Drugs
migoprotafib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05487235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487235.